In our previous studies, it has been proved that ERK1/2-NF-κB signaling pathway is involved in the pathogenesis of inflammatory infiltration in the early stage of chronic renal allograft dysfunction (CRAD),but what remained unclear is the up-stream signals to activate above signaling pathway, especially the extracellular signal molecules. In above studies, we also observed the up-regulated expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the renal tissue of CRAD rat model and human transplant recipients. It is suggested by the results of our initial studies that TIMP-2 might activate ERK1/2-NF-κB signaling pathway via its interaction with membrane-type 1 matrix metalloproteinase (MT1-MMP) and play key roles in CRAD. This project is designed to prove that up-regulated TIMP-2 expression in CRAD kidney tissue is tightly correlated with the development of CRAD and confirm that TIMP-2 is a key extracellular molecule in activating ERK1/2-NF-κB signaling pathway by means of molecular cloning,RNAi and Co-IP techniques,and therefore to elucidate the mechanism for TIMP-2 to interact with MT1-MMP and activate ERK1/2-NF-κB signal pathway, providing new idea for the prevention and treatment in the early stage of CRAD.
我们前期证实ERK1/2-NF-κB信号通路参与慢性移植肾失功(CRAD)早期炎症细胞浸润发生机制,但对CRAD过程中ERK1/2-NF-κB信号通路激活的上游信号事件特别是胞外信号分子尚不清楚。我们发现临床CRAD患者和大鼠移植肾组织基质金属蛋白酶抑制剂-2(TIMP-2)表达上调,结合我们的预实验结果推测TIMP-2可能是通过与膜型基质金属蛋白酶(MT1-MMP)相互作用激活ERK1/2-NF-κB信号通路并进而在CRAD中发挥了关键作用。本项目拟利用分子克隆、RNAi和Co-IP等分子生物学技术在HK-2细胞和CRAD大鼠模型进一步证实CARD肾组织TIMP-2表达上调与CARD发生发展密切相关;证明TIMP-2是激活ERK1/2-NF-κB信号通路的关键胞外分子;探索TIMP-2与MT1-MMP相互作用并进而激活ERK1/2-NF-κB信号通路的机制,为CRAD早期防治提供新思路。
项目采用CRAD大鼠模型,应用TIMP2-shRNA慢病毒作为干预手段,在国内外率先在CRAD体内实验证实TIMP2表达上调激活ERK1/2-NF-κB信号通路,促进移植肾早期炎症细胞浸润、VSMCs移行,促进慢性移植肾IF/TA。在本项目的资助的研究中我们发现,CRAD肾组织中存在着TIMP2表达上调,干预实验证实其上调可以激活ERK1/2-NF-κB信号通路,进而介导移植肾早期炎症因子表达,进而促进炎症细胞浸润和VSMCs移行;而采用TIMP2-慢病毒干预后,ERK1/2-NF-κB信号通路活化得到抑制,结果移植肾炎症浸润得到改善,CRAD的进展得到一定程度控制;MT1-MMP转染HK2细胞实验显示,在转染了MT1-MMP的质粒后,蛋白印迹初步结果显示TIMP-2的表达上升、p-ERK1/2、pp-65、ICAM1的蛋白表达均上调,初步说明MT1-MMP的过表达可以上调ERK信号通路,继而激活NF-κB信号通路,导致CRAD早期炎症细胞浸润。本研究在国际上首次探讨了TIMP2参与慢性移植肾失功发病机制的具体机制及其信号通路,为未来临床应用TIMP2阻断剂治疗慢性移植肾失功提供了实验基础,有助于提高移植肾长期存活率。在执行本研究计划中我们共发表标注本基金的SCI论文4篇。
{{i.achievement_title}}
数据更新时间:2023-05-31
妊娠对雌性大鼠冷防御性肩胛间区棕色脂肪组织产热的影响及其机制
外泌体在胃癌转移中作用机制的研究进展
High Performance Van der Waals Graphene-WS2-Si Heterostructure Photodetector
中温固体氧化物燃料电池复合阴极材料LaBiMn_2O_6-Sm_(0.2)Ce_(0.8)O_(1.9)的制备与电化学性质
奥希替尼治疗非小细胞肺癌患者的耐药机制研究进展
IR及ERK1/2MAPK-GSK-3β信号参与慢性移植肾IF/TA早期发病机制的实验研究
锌指蛋白A20防治同种异体移植肝慢性失功及其机制研究
Y-27632对慢性移植肾失功的治疗作用及分子机制:依赖于调节细胞紧密连接/VHL通路拮抗EMT的新途径
免疫炎症因子SNPs与他克莫司代谢相关蛋白调控基因在肝移植受者移植物慢性失功和肾毒性损伤的作用机制研究